Screener
Pelthos Therapeutics PTHS Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $10.91M— | $9.39M— | $7.41M— | $0— | $0— | ||
| $1.67M— | $1.67M— | $2.32M— | $0— | $0— | ||
| $9.23M— | $7.72M— | $5.09M— | $0— | $0— | ||
| 84.7%— | 82.2%— | 68.7%— | —— | —— | ||
| $186K-4.1% | $374K+31.2% | $145K-65.1% | $514.81K+3,874% | $194K-58.4% | ||
| $21.1M+1,187% | $18.47M+1,100% | $19.63M+1,101% | $2.72M— | $1.64M— | ||
| $23.99M+1,208% | —— | —— | —— | $1.83M-3.1% | ||
| -$13.09M-614% | -$12M-558% | -$15.36M-650% | -$3.23M-83.1% | -$1.83M+5.2% | ||
| -120%— | -127.8%— | -207.4%— | —— | —— | ||
| $2.35M+1,656% | $1.31M+1,117% | $1.35M+3,351% | $218K— | $134K— | ||
| $2.85M+2,227% | -$16.58M-16,158% | -$1.34M-479% | -$218.52K-2,801% | -$134K+78.7% | ||
| -$10.24M-420% | -$28.59M-1,384% | -$16.7M-885% | -$3.45M-94.7% | -$1.97M+23.2% | ||
| $0— | -$6.92M— | -$465K— | $0— | $0— | ||
| -$10.24M-420% | -$21.66M-1,025% | -$16.24M-858% | -$3.45M-94.7% | -$1.97M+23.2% | ||
| -93.9%— | -230.7%— | -219.3%— | —— | —— | ||
| -$3.09+3.7% | —— | —— | —— | -$3.21+10.0% | ||
| -$11.59M-532% | -$10.79M-491% | -$14.68M-617% | -$3.23M-83.1% | -$1.83M+5.2% | ||
| -106.3%— | -114.9%— | -198.3%— | —— | —— | ||
| -$13.09M-614% | -$12M-558% | -$15.36M-650% | -$3.23M-83.1% | -$1.83M+5.2% |
FAQ
- What is Pelthos Therapeutics's revenue?
- Pelthos Therapeutics (PTHS) generated $27.7M in revenue over the trailing twelve months.
- Is Pelthos Therapeutics profitable?
- Pelthos Therapeutics is not currently profitable: it reported a net loss of $51.6M over the trailing twelve months, a -186.2% net margin.
- What are Pelthos Therapeutics's profit margins?
- Gross margin is 79.6% and operating margin is -157.7%, with a -186.2% net margin.
- What is Pelthos Therapeutics's earnings per share?
- Pelthos Therapeutics's diluted EPS over the trailing twelve months is $-13.44.
- Where does Pelthos Therapeutics's income statement data come from?
- Every line is extracted from Pelthos Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
